Manufacturer
GLAXOSMITHKLINE BIOLOGICALS S.A
Contents
Human papillomavirus vaccine (recombinant) types 16 & 18 (AS04 adjuvanted)
Indication
Prevention of premalignant anogenital lesions & cervical & anal cancers caused by oncogenic human papillomavirus types 16 & 18.
Instruction
IM Patient ≥15 yr 3 doses 0.5 mL each at 0, 1, 6 mth, 10-14 yr 2 doses 0.5 mL each. 2nd dose given between 5 & 13 mth after 1st dose.
Drug interaction
Adequate response may not be elicited w/ immunosuppressants.
Malaysia
